Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A pilot study of SRL 172 (killed Mycobacterium vaccae) in healthy chronic hepatitis B carriers and hepatitis B vaccine non-responders|
|Citation:||Human Vaccines and Immunotherapeutics, 2006; 2(1):8-13|
|Paul N. Goldwater|
|Abstract:||AIM: To assess possible development of immunity to HBV by the use of hepatitis B vaccine in combination with the adjuvant M. vaccae (SRL 172) in healthy chronic HBsAg carriers and in healthy non-responders to hepatitis B vaccine. Hypothesis: To utilise the known immuno-stimulatory effects of SRL 172 (heat-killed M. vaccae) on chronic carriers of HBV and non-responders to hepatitis B vaccine to overcome the respective ‘immune-tolerance’ and ‘immune blindness’ observed in these conditions and develop immunity to hepatitis B. METHOD: 35 suitable healthy HBsAg carriers were randomised to receive hepatitis B vaccine together with either placebo or SRL172 by the intradermal route on one occasion. 23 HB vaccine non-responders were randomised in the same way, and similarly given vaccine with either SRL 172 or placebo. The HBsAg carrier subjects were followed-up for 12 months to monitor changes in HBV markers, anti-HBs, clinical chemistry, immunological and clinical status. The HB vaccine non-responders were reassessed for the development of anti-HBs at 3 months post-immunisation. RESULTS: This pilot study provided evidence that SRL172 was moderately well tolerated and safe. One HB vaccine/placebo recipient (with initial pre-vaccination high HBV load) became HBV DNA negative and remained so for the 12 month duration of the study. Vaccine plus SRL172 helped induce measurably higher anti-HBs titres in HB vaccine non-responders, however, because of relatively small participant numbers, statistically significant results were not obtained. CONCLUSION: Based on the development of anti-HBs in non-responders, the non-proprietary mixing of vaccine with SRL172 does not destroy immunogenicity of the vaccine and thus provides an opportunity to conduct further studies of this combination in hepatitis B vaccine non-responders. HB vaccine plus SRL 172 when given on one occasion is ineffective in treating HBsAg carriers. Interesting differences between the treatment groups were observed in HB viral load responses at 3 months post-vaccination. Consideration should be given to further studies using multi-dose HB vaccine regimens.|
Hepatitis B, Chronic
Hepatitis B Vaccines
Hepatitis B Antibodies
|Rights:||© 2006 Landes Bioscience|
|Appears in Collections:||Aurora harvest 5|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.